eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
SCImago Journal & Country Rank

vol. 43
Review paper

MicroRNAs in pancreatic cancer diagnosis and therapy

Robert Słotwiński, Gustaw Lech, Sylwia Małgorzata Słotwińska

(Centr Eur J Immunol 2018; 43 (3): 314-324)
Online publish date: 2018/10/30
View full text
Get citation
JabRef, Mendeley
Papers, Reference Manager, RefWorks, Zotero
Pancreatic cancer remains a disease with very poor prognosis (only 5-6% of patients are still alive after five years). Attempts to improve the results of treatment of pancreatic cancer focus on a better understanding of the pathogenesis, and non-invasive diagnostic methods (genetic testing from peripheral blood), which would create the possibility of early diagnosis and early surgical treatment before the onset of metastasis. New hopes for the improvement of early diagnosis and treatment of pancreatic ductal adenocarcinoma (PDAC) are associated with genetic testing of microRNA expression changes. A large body of evidence has revealed that microRNAs are aberrantly expressed in the serum and in cancer tissues and elicit oncogenic or tumour-suppressive functions. Selected microRNAs can distinguish pancreatic ductal adenocarcinoma from non-cancerous lesions of the pancreas. This review focuses on the involvement of microRNAs in the early diagnosis of pancreatic cancer. Research results related to the development of a novel therapeutic strategy based on the modulation of microRNA expressions for a better outcome in patients with pancreatic cancer are also presented.

pancreatic cancer, microRNA expression, diagnosis, anticancer therapy

Shaw VE, Lane B, Jenkinson C, et al. (2014): Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease. Mol Cancer 13: 114.
Yako YY, Kruger D, Smith M, Brand M (2016): Cytokines as biomarkers of pancreatic ductal adenocarcinoma: A Systematic Review. PLoS One 11:e0154016.
Słotwiński R, Słotwińska SM (2016): Diagnostic value of selected markers and apoptotic pathways for pancreatic cancer. Cent Eur J Immunol 41: 392-403.
Słotwiński R, Słotwińska SM (2016): Dysregulation of signaling pathways associated with innate antibacterial immunity in patients with pancreatic cancer. Cent Eur J Immunol 41: 404-418.
Kaur S, Baine MJ, Jain M, et al. (2012): Early diagnosis of pancreatic cancer: challenges and new developments. Biomark Med 6: 597-612.
Krol J, Loedige I, Filipowicz W (2010): The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet 11: 597-610.
Bartel DP (2004): MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
Cai X, Hagedorn CH, Cullen BR (2004): Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs. RNA 10: 1957-1966.
Lee Y, Han AJ, et al. (2003): The nuclear RNase III Drosha initiates microRNA processing. Nature 425: 415-419.
Suzuki H, Maruyama R, Yamamoto E, Kai M (2012): DNA methylation and microRNA dysregulation in cancer. Mol Oncol 6: 567-578.
Chang TC, Wentzel EA, Kent OA, et al. (2007): Transactivation of miR-34a by p53 broadly influence gene expression and promotes apoptosis. Mol Cell 26: 745-752.
Liu R, Zhang C, Hu Z, et al. (2011): A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 47: 784-791.
Vogt M, Munding J, Grumer M, et al. (2001): Frequent concominant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial and renal cell carcinomas and soft tissue sarcomas. Virchows Arch 458: 313-322.
Jones S, Zhang X, Parsons DW, et al. (2008): Core signaling pathways in human pancreatic cancer revealed by global genomic analyses. Science 321: 1801-1806.
Sun L, Chua CYX, Tian W, et al. (2015): MicroRNA signaling pathway network in Pancreatic ductal adenocarcinoma. J Genet Genomics (JGG) 42: 563-577.
Hanahan D, Weinberg RA (2000): The hallmarks of cancer. Cell 100: 57-70.
Hanahan D, Weinberg RA (2011): Hallmarks of Cancer: The Next Generation. Cell 144: 646-674.
Dong J, Zhao YP, Zhou L, et al. (2011): Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells. Arch Med Res 42: 8-14.
Zhang R, Li M, Zang W, et al. (2014): MiR-148a regulates the growth and apoptosis in pancreatic cancer by targeting CCKBR and Bcl-2. Tumor Biol 35: 837-844.
Guo R, Wang Y, Shi WY, et al. (2012): MicroRNA miR-491-5p targeting both TP53 and Bcl-XL induces cell apoptosis in SW1990 pancreatic cancer cells through mitochondria mediated pathway. Molecules 17: 14733-14747.
Druz A, Chen YC, Guha R, et al. (2013): Large-scale screening identifies a novel microRNA, miR-15a-3p, which induces apoptosis in human cancer cell lines. RNA Biol 10: 287-300.
Zang W, Wang Y, Wang T, et al. (2015): miR-663 attenuates tumor growth and invasiveness by targeting eEFIA2 in pancreatic cancer. Mol Cancer 14: 37.
Stark A, Brennecke J, Bushati N, et al. (2005): Animal microRNAs confer robustness to gene expression and have a significant impact on 3’UTR evolution. Cell 123: 1133-1146.
Cui Q, Yu Z, Purisima EO, Wang E (2006): Principles of microRNA regulation of a human cellular signaling network. Mol Syst Biol 2: 46.
Cui Q, Yu Z, Pan Y, et al. (2007): MicroRNAs preferentially target the genes with high transcriptional regulation complexity. Biochem Biophys Res Commun 352: 733-738.
Lynn FC (2009): Meta-regulation: microRNA regulation of glucose and lipid metabolism. Trends Endocrinol Metab 20: 452-459.
Mitchell PS, Parkin RK, Kroh EM, et al. (2008): Circulating microRNAs as stable blood-based markers for cancer detection. PNAS 105: 10513-10518.
Weber JA, Baxter DH, Zhang S, et al. (2010): The microRNA spectrum in 12 body fluids. Clin Chem 56: 1733-1741.
Lan H, Lu H, Wang X, Jin H (2015): MicroRNAs as Potential Biomarkers in Cancer: Opportunities and Challenges. Biomed Res Int 2015; 125094.
Friedman RC, Farh KK-H, Burge CB, Bartel DP (2009): Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19: 92-105.
Davidson-Moncada J, Papavasiliou FN, Tam W (2010): MicroRNAs of the immune system: roles in inflammation and cancer. Ann NY Acad Sci 1183: 183-194.
O’Connell RM, Rao DS, Chaudhuri AA, Baltimore D (2010): Physiological and pathological roles for micro RNAs in the immune system. Nat Rev Immunol 10: 111-122.
Koturbash I, Zemp FJ, Pogribny I, Kovalchuk O (2011): Small molecules with big effects: the role of microRNAome in cancer and carcinogenesis. Mutat Res 722: 94-105.
Hernandez YG, Lucas AL (2016): MicroRNA in pancreatic ductal adenocarcinoma and its precursor lesions. World J Gastrointest Oncol 8: 18-29.
Subramani R, Gangwani L, Nandy SB, et al. (2015): Emerging roles of microRNAs in pancreatic cancer diagnosis, therapy and prognosis. Int J Oncol 47: 1203-1210.
Jemal A, Siegiel R, Xu J, Ward E (2010): Cancer statistics. CA Cancer J Clin 60: 277-300.
Bosetti C, Bertuccio P, Malvezzi M, et al. (2013): Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980. Ann Oncol 24: 2657-2671.
Siegel RL, Miller KD, Jemal A (2015): Cancer statistics. CA Cancer J Clin 65: 5-29.
Raimondi S, Maisonneuve P, Lowenfels AB (2009): Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol 6: 699-708.
Howlader N, Noone AM, Krapcho M, et al. (2013): SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations), National Cancer Institute. Bethesda. Accessed at http://seer.cancer.gov/csr/1975_2009_pops09 on 8 August 2013.
Winter JM, Cameron JL, Campbell KA, et al. (2006): 1423 pancreaticoduodenectomies for pancreatic cancer: a single institution experience. J Gastrointest Surg 10: 1199-1211.
Egawa S, Takeda K, Fukuyama S, et al. (2004): Clinicopathological Aspects of Small Pancreatic Cancer. Pancreas 28: 235-240.
Ariyama J, Suyama M, Ogawa K, Ikarai T (1986): Screening of pancreatic neoplasms and diagnostic rate of small pancreatic neoplasns. Nihon Rinsho 44: 1729-1734.
Szafrańska AE, Doleshal M, Edmunds HS, et al. (2008): Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. Clin Chem 54: 1716-1724.
Szafrańska AE, Davison TS, John J, et al. (2007): MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene 26: 4442-4452.
Munding JB, Adai AT, Maghnouj A, et al. (2012): Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma. Int J Cancer 131: E86-E95.
Lee LS, Szafrańska-Schwarzbach AE, Wylie D, et al. (2014): Investigating MicroRNA expression profiles in pancreatic cystic neoplasms. Clin Transl Gastroenterol 5: e47.
Hong TH, Park IY (2014): MicroRNA expression profiling of diagnostic needle aspirates from surgical pancreatic cancer specimens. Ann Surg Treat Res 87: 290-297.
Zhao W-G, Yu S-A, Lu Z-H, et al. (2010): The miR-217 microRNA functions as a potential tumor suppressor in pancreatic ductal adenocarcinoma by targeting KRAS. Carcinogenesis 31: 1726-1733.
Jamieson NB, Morran DC, Morton JP, et al. (2012): MicoRNA molecular profiles associated with diagnosis, clinicopathologic criteria, and overall survival in patients with resectable pancreatic ductal adenocarcinoma. Clin Cancer Res 18: 534-545.
Schultz NA, Werner J, Willenbrock H, el al. (2012): MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma. Mod Pathol 25: 1609-1622.
Hamada S, Satoh K, Fujibuchi W, et al. (2012): MiR-126 acts as a tumor suppressor in pancreatic cancer cells via the regulation of ADAM9. Mol Cancer Res 10: 3-10.
Hamada S, Satoh K, Miura S, et al. (2013): MiR-197 induces epithelial-mesenchymal transition in pancreatic cancer cells by targeting p120 catenin. J Cel Physiol 228: 1255-1263.
Zhu Z, Xu Y, Zhao J, et al. (2015): miR-367 promotes epithelial-to-mesenchymal transition and invasion of pancreatic ductal adenocarcinoma cells by targeting the Smad7-TGF-b signalling pathway. Brit J Cancer 112: 1367-1375.
Papaconstantinou IG, Manta A, Gazouli M, et al. (2013): Expression of microRNAs in patients with pancreatic cancer and its prognostic significance. Pancreas 42: 67-71.
Jiao LR, Frampton AE, Jacob J, et al. (2012): MicroRNAs targeting oncogenes are down-regulated in pancreatic malignant transformation from benign tumors. PLoS One 7: e32068.
Meng F, Henson R, Wehbe-Janek H, et al. (2007): MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133: 647-658.
Frankel LB, Christoffersen NR, Jacobsen A, et al. (2008): Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem 283: 1026-1033.
Permuth-Wey J, Chen YA, Fisher K, et al. (2015): A genome-wide investigation of microRNA expression identifies biologically-meaningful microRNAs that distinguish between high-risk an low-risk intraductal papillary mucinous neoplasms of pancreas. PLoS One 10: e0116869.
Lubezky N, Loewenstein S, Ben-Haim M, et al. (2013): MicroRNA expression signatures in intraductal papillary mucinous neoplasm of pancreas. Surgery 153: 663-672.
Yu J, Li A, Hong SM, et al. (2012): MicroRNA alterations of pancreatic intraepithelial neoplasias. Clin Cancer Res 18: 981-992.
Slater EP, Strauch K, Rospleszcz S, et al. (2014): MicroRNA-196a and -196b as potential biomarkers for the early detection of familial pancreatic cancer. Transl Oncol 7: 464-471.
Ryu JK, Hong SM, Karikari CA, et al. (2010): Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology 10: 66-73.
du Rieu MC, Torrisani J, Selves J, et al. (2010): MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem 56: 603-612.
Frampton AE, Krell J, Prado MM, et al. (2016): Prospective validation of microRNA signatures for detecting pancreatic malignant transformation in endoscopic-ultrasound guided fine-needle aspiration biopsies. Oncotarget 7: 28556-28569.
Kasaka N, Iguchi H, Ochiya T (2010): Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101: 2087-2092.
Wang J, Chen J, Chang P, et al. (2009): MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila Pa) 2: 807-813.
Liu J, Gao Y, Li Z, et al. (2012): Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer 131: 683-691.
Li A, Yu J, Kim H, et al. (2013): MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res 19: 3600-3610.
Schultz NA, Dehlendorff C, Jensen BV, et al. (2014): MicroRNA Biomarkers in Whole Blood for Detection of Pancreatic Cancer. JAMA 311: 392-404.
Kojima M, Sudo H, Kawauchi J, et al. (2015): MicoRNA markers for diagnosis of pancreatic and biliary-tract cancers. PLoS One 10: e0118220.
Kong X, Du Y, Wang G, et al. (2011): Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be potential marker for poor prognosis Dig Dis Sci 56: 602-609.
Morimura R, Komatsu S, Ichikawa D, et al. (2011): Novel diagnostic value of circulating miR-18a in plasma of patients with pancreatic cancer. Br J Cancer 105: 1733-1740.
Kawaguchi T, Komatsu S, Ichikawa D, et al. (2013): Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer 108: 361-369.
Komatsu S, Ichikawa D, Takeshita H, et al. (2014): Circulating miR-18a: a sensitive cancer screening biomarker in human cancer. In Vivo 28: 293- 297.
Abue M, Yikoyama M, Shibuya R, et al. (2015): Circulating miR-483-3p and miR-21 is highly expressed in plasma of pancreatic cancer Int J Oncol 46: 539-547.
Liu R, Chen X, Du Y, et al. (2012): Serum microRNA expression profile as a biomarker in the diagnosis and prognosis of pancreatic cancer. Clin Chem 58: 610-618.
Deng T, Yuan Y, Zhang Chu, et al. (2016): Identification of circulating miR-25 as a potential biomarker for pancreatic cancer diagnosis. Cell Physiol Biochem 39: 1716-1722.
Madhavan B, Yue S, Galli U, et al. (2015): Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity. Int J Cancer 136: 2616-2627.
Costello E, Greenhalf W, Neoptolemos JP (2012): New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol 9: 435-444.
Kishikawa T, Otsuka M, Ohno M, et al. (2015): Circulating RNAs as new biomarkers for detecting pancreatic cancer. World J Gastroenterol (WJG) 21: 8527-8540.
Li Y, Sarkar FH (2016): MicroRNA targeted therapeutic approach for pancreatic cancer 12: 326-337.
Buchsbaum DJ, Croce CM (2014): Will detection of microRNA biomarkers in blood improve the diagnosis and survival of patients with pancreatic cancer? JAMA 311: 363-365.
Cortez MA, Bueso-Ramos C, Ferdin J, et al. (2011): MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol 8: 467-477.
Link A, Becker V, Goel A, et al. (2012): Feasibility of fecal microRNAs as novel biomarkers for pancreatic cancer. PLoS One 7:e42933.
Kosaka N, Izumi H, Sekine K, Ochiya T (2010): microRNA as a new immune-regulatory agent in breast milk. Silence 1: 7.
Li H, Huang S, Guo C, et al. (2012): Cell-Free Seminal mRNA and MicroRNA Exist in Different Forms. PLoS One 7: e34566.
Tang S, Bonaroti J, Unlu S, et al. (2013): Sweating the small stuff: microRNAs and genetic changes define pancreatic cancer. Pancreas 42: 740-759.
Liu M, Du Y, Gao J, et al. (2013): Aberrant expression miR-196a is associated with abnormal apoptosis, invasion, and proliferation of pancreatic cancer cells. Pancreas 42: 1169-1181.
Habbe N, Koostra JB, Mendell JT, et al. (2009): MicroRNA-155 is a biomarker of early pancreatic neoplasia. Cancer Biol Ther 8: 340-346.
Bloomston M, Frankel WL, Petrocca F, et al. (2007): MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297: 1901-1908.
Caponi S, Funel N, Frampton AE, et al. (2013): The good, the bad and ugly: a tale of miR-101, miR-21 and miR-155 in pancreatic intraductal papillary mucinous neoplasms. Ann Oncol 24: 734-741.
Papaconstantinou IG, Lykoudis PM, Gazouli M, et al. (2012): A review on the role of microRNA in biology, diagnosis, and treatment of pancreatic adenocarcinoma. Pancreas 41: 671-677.
Keklikoglou I, Hosaka K, Bender C, et al. (2015). MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes. Oncogene 34: 4867-4878.
Sun T, Kong X, Du Y, Li Z (2014): Aberrant MicroRNAs in pancreatic cancer: Researches and clinical implications. Gastroenterol Res Pract 2014: 386561.
Song S, Ajani JA (2013): The role of microRNAs in cancers of upper gastrointestinal tract. Nat Rev Gastroenterol Hepatol 10: 109-118.
Pramanik D, Campbell NR, Karikari C, et al. (2011): Restitution of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol Cancer Ther 10: 1470-1480.
Krutzfeldt J, Rajewsky N, Braich R, et al. (2005): Silencing of microRNAs in vivo with ‘antagomirs’. Nature 438: 685-689.
Esau CC (2008): Inhibition of microRNA with antisense oligonucleotides. Methods 44: 55-60.
Park JK, Lee EJ, Esau C, Schmittgen TD (2009): Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas 38: e190-e199.
Zhao Y, Zhao L, Ischenko I, et al. (2015): Antisense inhibition of microRNA-21 and miroRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer. Targ Oncol 10: 535-548.
Li Y, Chen Y, Li J, et al. (2017): Co-delivery of microRNA-21 antisense oligonucleotides and gemcitabine using nanomedicine for pancreatic cancer therapy. Cancer Sci 108: 1493-1503.
Sarkar S, Dubaybo H, Ali S, et al. (2013): Down-regulation of miR-221 inhibits proliferation of pancreatic cancer cells through up-regulation of PTEN, p27kip1, p57kip2, and PUMA. Am J Cancer Res 3: 465-477.
Bao B, Ali S, Banerjee S, et al. (2012): Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res 72: 335-345.
Yan HJ, Liu WS, Sun WH, et al. (2012): miR-17-5p inhibitor enhances chemosensitivity to gemcitabine via upregulating Bim expression in pancreatic cancer cells. Dig Dis Sci 57: 3160-3167.
Huang TC, Renuse S, Pinto S, et al. (2015): Identification of miR-145 targets through an integrated omics analysis. Mol Biosyst 11: 197-207.
Li Y, VandenBoom TG, Wang Z, et al. (2010): miR-146a suppresses invasion of pancreatic cancer cells. Cancer Res 70: 1486-1495.
Pramanik D, Camphel NR, Karikari C, et al. (2013): Putative tumor suppressor gene SELIL was downregulated by aberrantly upregulated has-mir-155 in human pancreatic ductal adenocarcinoma. Mol Carcinog 53: 711-712.
Bhatti I, Lee A, James V, et al. (2011): Knockdown of microRNA-21 inhibits proliferation and increases cell death by targeting programed cell 4 (PDCD4) in pancreatic ductal adenocarcinoma. J Gastrointest Surg 15: 199-208.
Kadera BE, Li L, Toste PA, et al. (2013): MicroRNA-21 in pancreatic ductal adenocarcinoma tumor-associated fibroblasts promotes metastasis. PLoS One 8: e71978.
Hwang JH, Voortman J, Giovannetti E, et al. (2010): Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PloS One 5: e10630.
Paik WH, Kim HR, Park JK, et al. (2013): Chemosensitivity Induced by Down-regulation of MicroRNA-21 in Gemcitabine-resistant Pancreatic Cancer Cells by Indole-3-Carbinol. Anticancer Res 33: 1473-1482.
Li Y, VandenBoom TG, Kong D, et al. (2009): Up- regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res 69: 6704-6712.
Liu P, Liang H, Xia Q, et al. (2013): Resveratrol induces apoptosis of pancreatic cancer cells by inhibiting miR-21 regulation of BCL-2 expression. Clin Transl Oncol 15: 741-746.
Liu C, Cheng H, Shi S, et al. (2013): MicroRNA-34b inhibits pancreatic cancer metastasis through repressing Smad3. Curr Mol Med 13: 467-478.
Nalls D, Tang SN, Rodova M, et al. (2011): Targeting epigenetic regulation of miR-34a for treatment of pancreatic cancer by inhibition of pancreatic cancer stem cells. PLoS One 6: e24099.
Arora S, Swaminathan SK, Kirtane A, et al. (2014): Synthesis characterization and evaluation of poly(D,L-lactide-co-glycolide)-based nanoformulation of miRNA-150 potential implications for pancreatic cancer therapy. Int J Nanomedicine 9: 2933-2942.
Hu QL, Jiang QY, Jin X, et al. (2013): Cationic microRNA-delivering nanovectors with bifunctional peptides for efficient treatment of PANC-1 xenograft model. Biomaterials 34: 2265-2276.
Mittal A, Chitkara D, Behrman SW, Mahato RI (2014): Efficacy of gemcitabine conjugated and miRNA-205 complexed micelles for treatment of advanced pancreatic cancer. Biomaterials 35: 7077-7087.
Kumar V, Mondal G, Slavik P, et al. (2015): Codelivery of Small Molecule Hedgehog Inhibitor and miRNA for Treating Pancreatic Cancer. Mol Pharm 12: 1289-1298.
Li H, Wu Y, Li P (2017): MicroRNA452 suppresses pancreatic cancer migration and invasion by directly targeting Bcellspecific Moloney murine leukemia virus insertion site 1. Oncol Lett 14: 3235-3242.
He Z, Xia Y, Pan C, et al. (2015): Upregulation of miR452 inhibits metastasis of nonsmall cell lung cancer by regulating BMI1. Cell Physiol Biochem 37: 387398.
Liu SG, Qin XG, Zhao BS, et al. (2013): Differential expression of miRNAs in esophageal cancer tissue. Oncol Lett 5: 16391642.
MacKenzie TN, Mujumdar N, Banerjee S, et al. (2013): Triptolide induces the expression of miR-142-3p: A negative regulator of heat shock protein 70 and pancreatic cancer cell proliferation. Mol Cancer Ther 12: 1266-1275.
Qazi AMI, Gruzdyn O, Semaan A, et al. (2012): Restoriation of E-catherin expression in pancreatic ductal adenocarcinoma treated with microRNA-101. Surgery 152: 704-713.
Tomasetti M, Amati M, Santarelli L, Neuzil J (2016): MicroRNA in metabolic re-programming and their role in tumorigenesis. Int J Mol Sci 17: 754-773.
Hanahan D, Weinberg RA (2011): Hallmarks of cancer: The next generation. Cell 144: 646-674.
Fei X, Qi M, Wu B, et al. (2012): MicroRNA-195-5p suppresses glucose uptake and proliferation of human bladder cancer T24 cells by regulating GLUT3 expression. FEBS Lett 586: 392-397.
Ji W, Sun B, Su Ch (2017): Targeting MicroRNAs in Cancer Gene Therapy. Genes (Basel) 8: 21.
Baj-Krzyworzeka M, Szatanek R, Węglarczyk K, et al. (2007): Tumor-derived microvesicles modulate biological activity of human monocytes. Immunol Lett 113: 76-82.
Belting M, Wittrup A (2008): Nanotubules, exosomes, and nucleic acid-binding peptides provide novel mechanisms of intercellular communication in eukaryotic cells: implications in health and disease. J Cell Biol 183: 1187-1191.
Ratajczak J, Miekus K, Kucia M, et al. (2006): Embryonic stem cell-derived microvesicles reprogram hematopoietic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukemia 20: 847-856.
Laterza OF, Lim L, Garrett-Engele PW, et al. (2009): Plasma MicroRNAs as diagnostically sensitive and specific biomarkers of tissue injury. Clin Chem 55: 1977-1983.
Liu J, van Mil A, Vrijsen K, et al. (2011): MicroRNA-155 prevents necrotic cell death in human cardiomyocyte progenitor cells via targeting RIP1. J Cell Mol Med 15: 1474-1482.
Ross SA, Davis CD (2011): MicroRNA, Nutrition, and cancer prevention. Adv Nutr 2: 472-485.
Quick links
© 2019 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe